Abstract
Human peptide transporter 1 (PEPT1) mediates the cellular uptake of di- and tripeptides and peptide-like drugs in the small intestine. In the present study, we examined the regulation of PEPT1 by anticancer drugs in the gastric cancer cell line MKN45. PEPT1 was expressed and functioned in MKN45 cells. The transport activity and mRNA expression of the facilitative glucose transporter 1 (GLUT1) were significantly decreased by 5-fluorouracil treatment, but those of PEPT1 were slightly increased. Cisplatin treatment affected neither PEPT1 nor GLUT1 activity. In conclusion, PEPT1 expressed in MKN45 cells are resistant against the cellular injury induced by 5-fluorouracil and cisplatin.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antimetabolites, Antineoplastic / pharmacology*
-
Antineoplastic Agents / pharmacology*
-
Cisplatin / pharmacology*
-
Fluorouracil / pharmacology*
-
Glucose Transporter Type 1 / biosynthesis
-
Glucose Transporter Type 1 / drug effects
-
Glucose Transporter Type 1 / physiology
-
Humans
-
Peptide Transporter 1
-
RNA, Messenger / biosynthesis
-
Stomach Neoplasms / pathology*
-
Symporters / biosynthesis*
-
Symporters / drug effects
-
Symporters / physiology*
-
Tumor Cells, Cultured
Substances
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Glucose Transporter Type 1
-
Peptide Transporter 1
-
RNA, Messenger
-
SLC15A1 protein, human
-
SLC2A1 protein, human
-
Symporters
-
Cisplatin
-
Fluorouracil